Qdenga (Dengue Tetravalent Vaccine)

Qdenga (dengue tetravalent vaccine) is a vaccine that helps protect against dengue disease. It can be given to adults, adolescents, and children from 4 years of age. Dengue disease is a mosquito-borne tropical disease caused by the dengue virus. This disease leads to mild, flu-like signs and symptoms in most individuals. However, a small number of patients develop serious disease, with potentially fatal bleeding and organ damage. This vaccine contains attenuated (weakened) versions of dengue virus serotypes (varieties) 1, 2, 3, and 4.

Recommended Dosage:
The recommended dosage of Qdenga is administered by your clinician or nurse as an injection under the skin (subcutaneous injection) in the upper arm. It must not be administered by intravascular, intradermal, or intramuscular injection. This vaccine is administered as:

1st dose of 0.5 mL at Month 0
2nd dose of 0.5 mL at Month 3

To get the complete benefit of protection from this live, attenuated vaccine, patients should receive both doses 3 months apart. Patients should schedule their second dose after receiving their first dose. The second dose is given 3 months after the first dose. There are no data in adults aged above 60 years. Ask your healthcare professional (HCP) for advice on whether it is beneficial for you to receive this vaccine. Use this vaccine according to official recommendations. This vaccine must not be mixed in the same syringe with any other vaccine or other parenteral medicinal products.

If a scheduled dose of Qdenga (dengue tetravalent vaccine) is missed, let your doctor decide when to get the missed dose.

• Qdenga live, attenuated vaccine may rarely cause serious allergic reactions. Watch out for all vaccine recipients for bare minimum 15 minutes after vaccination. Individuals with known serious allergies to any vaccine ingredient should avoid receiving this vaccine unless required and supervised by a healthcare professional.
• Before vaccination, let your healthcare provider (HCP) know about any previous illnesses, current treatments, or immune system conditions. A complete medical history helps decide if this dengue tetravalent vaccine is effective and safe for you, particularly in people with weakened immunity or chronic diseases.
• Postponement of vaccination is advised in the event of moderate to severe illnesses. It's particularly prominent in the presence of a fever. Though a cold is classified as a mild illness, it's typically advisable to avoid any risk of side effects after a full recovery.
• Receiving this vaccine does not guarantee full prevention of all dengue infections. Predisposing factors of protection are previous exposure to the disease as well as its particular serotype. Despite having taken the vaccine, prevention measures like avoiding mosquito bites should remain in place due to the nature of vaccines lacking unerring protection.
  Some people, particularly younger people, report fainting or feeling dizzy post-vaccination. This usually happens due to heightened neurosensory activity. To guard against injury, patients must be seated or lying down before and during the vaccination and closely monitored for nuanced signs of stress or fainting.
• For women of childbearing age, it is advisable to have reliable means of contraception for a month post-vaccination. This is due to the use of Qdenga, which is a live vaccine; pregnancy must be avoided unless necessary because of risks concerning the unborn child.
• Let your doctor know about any medicines you are currently taking, including immunosuppressants or blood products. These may be responsible for interfering with the effectiveness of the vaccine or increasing the probability of side effects. Always follow healthcare advice regarding timing and combination with other treatments.
• Qdenga 0.5 mL vaccine may be administered with other vaccines, but injection sites must be different. Always consult your healthcare provider (HCP) about the schedule, as timing between live vaccines should follow recommended guidelines to avoid reduced immune responses.
• Some patients may experience fatigue, dizziness, or general malaise after vaccination. Until the effects of the vaccine are better understood, avoid operating a vehicle or heavy machinery. If you experience fainting or headaches, it is advised to rest until the symptoms subside entirely.
• Do not use this live, attenuated vaccine during pregnancy unless the risks are more favorable than the benefits. There’s very limited data on how it affects fertility or breastfeeding. Vaccination should be evaluated by the physician in terms of its impact on the baby or milk production before breastfeeding.

What documents are required to import QDENGA to India?

QDENGA (dengue tetravalent vaccine) live, attenuated vaccine, can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is QDENGA available in India?

QDENGA (dengue tetravalent vaccine) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Qdenga in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

QDENGA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of QDENGA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Qdenga 0.5mL live, attenuated vaccine price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source QDENGA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Qdenga®?

Qdenga® (also known as TAK-003) is a dengue vaccine. It is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all 4 dengue virus serotypes. It is designed to protect against any of these serotypes.

What is the Manufacturer's Name of Qdenga®?

Qdenga® is manufactured by Takeda.

Is Qdenga approved by the FDA?

The Qdenga vaccine is a dengue fever vaccine that has not been approved by the US Food and Drug Administration (FDA) as of May 5, 2025. While it is approved in Europe and other countries, including the UK, Argentina, Brazil, Indonesia, and Thailand. The FDA application was withdrawn in July 2023.

What is the dosage and form of Qdenga® live-attenuated vaccine supplied?

Qdenga is supplied as a 2-component vaccine. It consists of a vial containing lyophilised vaccine and solvent provided in the pre-filled syringe. The lyophilised vaccine must be reconstituted with the solvent before administration.

What are the most common side effects of Qdenga® live-attenuated vaccine?

The most common side effects of Qdenga® are injection site swelling, injection site itching, pain or inflammation of the nose or throat, injection site bruising, inflammation of the throat and tonsils, joint pain, and flu-like illness.

How much does Qdenga® live-attenuated vaccine cost in India?

Prices of Qdenga injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Qdenga 0.5mL dengue vaccine cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Qdenga® dengue vaccine be available in SAARC countries?

Apart from Gulf countries, Qdenga® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Qdenga® vaccines in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Qdenga® dengue tetravalent vaccine (live, attenuated) online in India?

Yes, one can buy Qdenga dengue vaccine online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Qdenga® vaccines through legal channels.

What are the storage conditions of Qdenga® dengue tetravalent vaccine (live, attenuated)?

Store this dengue vaccine in a refrigerator (2°C to 8°C). Do not freeze it. After reconstitution with the solvent provided, use it immediately. If not immediately, this vaccine must be used within 2 hours.